Given that current clinical practice uses the PSA test as an initial indicator of prostate cancer, we determined whether combining PSA test values with the selected flow cytometry predictors can strengthen diagnostic accuracy of the PSA test (the PSAFC prediction model, PSAFC-PM). This evidence concerns the gene KLK3 and prostate cancer.